Targeting NSCLC with Uncommon EGFR Mutations

Expert perspectives on the current landscape of molecular profiling in patients with non–small cell lung cancer.

Insight on EGFR-mutated non–small cell lung cancer’s impact on treatment options and overall patient prognoses.

Sandip Patel, MD, highlights the use of afatinib and mobocertinib, respectively, to treat NSCLC with rare EGFR-mutation variants.

Focusing on the broader treatment armamentarium for EGFR-mutated NSCLC, Sandip Patel, MD, considers possible sequencing and combination strategies.

Before closing out his discussion on NSCLC, Sandip Patel, MD, shares his excitement for evolving targeted strategies and improved patient outcomes.

Expert oncologist Roy Herbst, MD, PhD, provides a comprehensive overview of actionable mutations and molecular profiling in NSCLC.

Expert perspectives on molecular profiling strategies that may help overcome barriers to testing in non–small cell lung cancer.

Roy Herbst, MD, PhD, provides insight on the importance of EGFR mutations, both common and rare, in patients with non–small cell lung cancer.

Considerations for use of novel EGFR-targeted agents osimertinib, amivantamab, and poziotinib in NSCLC, in the context of respective clinical trial data.

Closing out his discussion on actionable mutations in NSCLC, Roy Herbst, MD, PhD, discusses optimal sequencing of EGFR-targeted agents.